PMID- 25979305
OWN - NLM
STAT- MEDLINE
DCOM- 20160322
LR  - 20181203
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Print)
IS  - 1051-0443 (Linking)
VI  - 26
IP  - 7
DP  - 2015 Jul
TI  - Transarterial hepatic chemoembolization with 70-150 microm drug-eluting beads: 
      assessment of clinical safety and liver toxicity profile.
PG  - 965-71
LID - S1051-0443(15)00296-1 [pii]
LID - 10.1016/j.jvir.2015.03.020 [doi]
AB  - PURPOSE: To assess the incidence and severity of adverse events (AEs) in the form 
      of clinical symptoms and liver/biliary injuries (LBI) in patients with hepatic 
      malignancies treated with transarterial chemoembolization using 70-150 mum 
      drug-eluting beads (DEBs). MATERIALS AND METHODS: A single-institution 
      retrospective analysis was performed in 37 patients (25 patients with 
      hepatocellular carcinoma and 12 patients with metastatic disease) who underwent 
      43 sessions of segmental/subsegmental 70-150 mum DEB transarterial 
      chemoembolization with doxorubicin (38 sessions) or irinotecan (5 sessions). 
      Patient inclusion criteria included the presence of the following lesion 
      features: small diameter (</= 3 cm), hypovascular, or with areas of residual 
      disease after other locoregional therapies. Mean tumor diameter was 3.4 cm. Mean 
      imaging and clinical follow-up periods were 171 days and 373 days, respectively. 
      Clinical, laboratory, and imaging data were used to identify and classify 
      clinically symptomatic AEs per session and LBI per patient according to the 
      National Cancer Institute Common Terminology Criteria for Adverse Events, version 
      4.03. Predictors for the occurrence of LBI were evaluated by logistic regression 
      analysis. RESULTS: No grade 4 or 5 AEs were recorded. Clinically symptomatic AEs 
      occurred in 29 (67.4%) sessions (grade 1-2, 28 sessions; grade 3, 1 session), all 
      constituting postembolization syndrome. Asymptomatic LBI occurred in 11 (29.7%) 
      patients (grade 1, 8 patients; grade 2, 3 patients). The mean time between 70-150 
      mum DEB transarterial chemoembolization session and appearance of LBI was 71 days 
      (range, 21-223 d). No predictive factors for the development of LBI were 
      identified. CONCLUSIONS: Transarterial chemoembolization with 70-150 mum DEBs was 
      considered safe in the present study population given the acceptably low 
      incidence and severity of AEs.
CI  - Copyright (c) 2015 SIR. Published by Elsevier Inc. All rights reserved.
FAU - Odisio, Bruno C
AU  - Odisio BC
AD  - Department of Interventional Radiology, Division of Diagnostic Imaging, The 
      University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1471, 
      Houston, TX 77030-3722. Electronic address: bcodisio@mdanderson.org.
FAU - Ashton, Aaron
AU  - Ashton A
AD  - Department of Diagnostic Radiology (A.A.), The University of Texas Medical School 
      at Houston, Houston, Texas.
FAU - Yan, Yuanqing
AU  - Yan Y
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      1400 Pressler Street, Unit 1471, Houston, TX 77030-3722.
FAU - Wei, Wei
AU  - Wei W
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      1400 Pressler Street, Unit 1471, Houston, TX 77030-3722.
FAU - Kaseb, Ahmed
AU  - Kaseb A
AD  - Department of Gastrointestinal (GI), Medical Oncology, Division of Cancer 
      Medicine, The University of Texas MD Anderson Cancer Center, 1400 Pressler 
      Street, Unit 1471, Houston, TX 77030-3722.
FAU - Wallace, Michael J
AU  - Wallace MJ
AD  - Department of Interventional Radiology, Division of Diagnostic Imaging, The 
      University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1471, 
      Houston, TX 77030-3722.
FAU - Vauthey, Jean N
AU  - Vauthey JN
AD  - Department of Surgical Oncology, Division of Surgery, The University of Texas MD 
      Anderson Cancer Center, 1400 Pressler Street, Unit 1471, Houston, TX 77030-3722.
FAU - Gupta, Sanjay
AU  - Gupta S
AD  - Department of Interventional Radiology, Division of Diagnostic Imaging, The 
      University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1471, 
      Houston, TX 77030-3722.
FAU - Tam, Alda L
AU  - Tam AL
AD  - Department of Interventional Radiology, Division of Diagnostic Imaging, The 
      University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1471, 
      Houston, TX 77030-3722.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P30CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20150605
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - 7673326042 (Irinotecan)
RN  - 80168379AG (Doxorubicin)
RN  - XT3Z54Z28A (Camptothecin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Bile Duct Diseases/diagnosis/etiology
MH  - Camptothecin/administration & dosage/adverse effects/*analogs & derivatives
MH  - Carcinoma, Hepatocellular/blood supply/pathology/*therapy
MH  - Chemoembolization, Therapeutic/adverse effects/*methods
MH  - Doxorubicin/*administration & dosage/adverse effects
MH  - *Drug Carriers
MH  - Female
MH  - Humans
MH  - Infarction/diagnosis/etiology
MH  - Irinotecan
MH  - Liver Neoplasms/blood supply/secondary/*therapy
MH  - Male
MH  - Middle Aged
MH  - Particle Size
MH  - Patient Safety
MH  - Portal Vein
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Texas
MH  - Time Factors
MH  - Treatment Outcome
MH  - Tumor Burden
MH  - Venous Thrombosis/diagnosis/etiology
PMC - PMC4484796
MID - NIHMS690690
EDAT- 2015/05/17 06:00
MHDA- 2016/03/24 06:00
PMCR- 2016/07/01
CRDT- 2015/05/17 06:00
PHST- 2014/09/18 00:00 [received]
PHST- 2015/03/11 00:00 [revised]
PHST- 2015/03/23 00:00 [accepted]
PHST- 2015/05/17 06:00 [entrez]
PHST- 2015/05/17 06:00 [pubmed]
PHST- 2016/03/24 06:00 [medline]
PHST- 2016/07/01 00:00 [pmc-release]
AID - S1051-0443(15)00296-1 [pii]
AID - 10.1016/j.jvir.2015.03.020 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2015 Jul;26(7):965-71. doi: 10.1016/j.jvir.2015.03.020. 
      Epub 2015 Jun 5.